Life
Briefing: Gilead to acquire immunology biotech, offers lifeline to Galapagos
Strategic angle: In today's Readout newsletter: Gilead to acquire an immunology biotech and Merck partners with Flagship company on IBD targets.
editorial-staff
1 min read
Updated 18 days ago
Gilead Sciences has announced its intention to acquire an immunology-focused biotech firm, a move that is poised to significantly impact the operational landscape for Galapagos.
This acquisition is expected to enhance Gilead's capabilities in immunology, potentially increasing throughput and capacity in drug development.
For Galapagos, this acquisition may serve as a lifeline, offering new opportunities for collaboration and resource sharing in the competitive biopharmaceutical market.